(AOF) – Amgen has announced the loss of 450 jobs, or less than 2% of its workforce (i.e. 25,200 employees in more than 50 countries): this is the second series of layoffs initiated this year by the American laboratory, after a first cart of 300 people in January. Amgen cites the need to “realign (its) spending base in the face of mounting drug price pressure and high levels of inflation”. For Reuters, this decision “highlights the impact of rapidly rising interest rates on the health sector”.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.